Acadia Pharmaceuticals (ACAD) Common Equity (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Common Equity of $1.2 billion for Q1 2026, up 63.1% year-over-year from $765.2 million in Q1 2025, and up 1.68% quarter-over-quarter from $1.2 billion in Q4 2025.
Acadia Pharmaceuticals (ACAD) Common Equity (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Common Equity rose 63.1% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 63.1% YoY), while the FY2025 annual figure was $1.2 billion, up 67.49% from the prior year.
- Common Equity for Q1 2026 stood at $1.2 billion, up from $1.2 billion in the prior quarter.
- The five-year high for Common Equity was $1.2 billion in Q1 2026, with the low at $362.2 million in Q3 2023.
- The 5-year median for Common Equity is $464.0 million (2024), against an average of $620.0 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity retreated 25.97% in 2022, then surged 69.72% in 2024.
- Acadia Pharmaceuticals' Common Equity stood at $400.4 million in 2022, then increased by 7.83% to $431.8 million in 2023, then soared by 69.72% to $732.8 million in 2024, then surged by 67.49% to $1.2 billion in 2025, then increased by 1.68% to $1.2 billion in 2026.
- Business Quant data shows ACAD's Common Equity at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $917.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Bn |
| Mar 31, 2026 | 1.25 Bn |
| Dec 31, 2025 | 1.23 Bn |
| Sep 30, 2025 | 917.27 Mn |
| Jun 30, 2025 | 822.38 Mn |
| Mar 31, 2025 | 765.24 Mn |
| Dec 31, 2024 | 732.79 Mn |
| Sep 30, 2024 | 577.18 Mn |
| Jun 30, 2024 | 516.70 Mn |
| Mar 31, 2024 | 464.04 Mn |
| Dec 31, 2023 | 431.76 Mn |
| Sep 30, 2023 | 362.17 Mn |
| Jun 30, 2023 | 395.79 Mn |
| Mar 31, 2023 | 374.26 Mn |
| Dec 31, 2022 | 400.41 Mn |
| Sep 30, 2022 | 425.69 Mn |
| Jun 30, 2022 | 434.85 Mn |
| Mar 31, 2022 | 444.80 Mn |
| Dec 31, 2021 | 540.89 Mn |
| Sep 30, 2021 | 566.96 Mn |